癌症單株抗體市場 - 全球產業規模、佔有率、趨勢、機會及預測（按單株抗體類型、單株抗體療法、應用、地區和競爭格局分類，2021-2031年）

全球癌症單株抗體市場預計將從 2025 年的 996.6 億美元成長到 2031 年的 2,449.5 億美元，複合年成長率為 16.17%。

這些實驗室設計的分子透過與癌細胞上的特定抗原結合發揮作用，有效促進免疫系統清除腫瘤細胞或抑制細胞生長訊號。惡性腫瘤在全球日益普遍，推動了這個產業的發展，使得生物目標療法的研發至關重要。美國癌症協會估計，光是2025年，美國就將新增2,041,910例癌症病例，凸顯了該領域的迫切性。日益加重的患者負擔，加上免疫療法藥物核准流程的加快，為該領域的蓬勃發展奠定了基礎。

儘管成長指標強勁，但由於生物製藥的研發和收購成本高昂，市場仍面臨許多障礙。高昂的生產資本往往導致價格上漲，限制了發展中地區的病患獲取，並給醫療報銷體系帶來巨大壓力。因此，嚴格的定價監管和高品質免疫療法的保險覆蓋不足仍然是限制這些先進治療方法市場滲透率和商業性擴充性的重要障礙。

市場促進因素

抗體工程技術的快速發展，特別是從標準單株抗體轉向高效抗體藥物複合體（ADC）和雙特異性抗體構建體的轉變，是推動市場發展的關鍵因素。這些先進的技術能夠將細胞毒性有效載荷精準地遞送至癌細胞，同時最大限度地降低全身毒性，有效克服了傳統療法的療效局限性和抗藥性問題。這項技術進步促成了重大的策略整合，各公司紛紛尋求收購獨特的平台以增強其產品組合。例如，強生公司於2024年3月宣布，已完成與Ambrax公司的全現金合併（總對價約20億美元），旨在整合其針對轉移性前列腺癌和其他固體癌的下一代ADC產品組合。這凸顯了業界向具有卓越治療特性的複雜生物製藥轉型的趨勢。

第二個關鍵促進因素是腫瘤研發和生產基礎設施投資的激增，以支持臨床管線和商業供應鏈。製藥開發商正投入大量資金建造端到端的生產設施，以確保這些複雜藥物的穩定供應。一個顯著的例子是Astra Zeneca於2024年5月宣布的15億美元資本投資計劃，用於在新加坡新建一座專門用於生產抗體藥物複合體的待開發區生產工廠。這股資金湧入主要源自於關鍵療法的巨大收入潛力。默克截至2024年2月的會計年度財務表現顯示，其旗艦抗體藥物Keytruda的銷售額成長了19%，達到250億美元，證實了該領域投資的強勁回報。

市場挑戰

開發和取得抗癌單株抗體的高昂成本是其市場持續擴張的一大障礙。由於這些生物製藥的生產過程複雜，且需要經過嚴格的臨床試驗，其定價通常超出醫療體系的承受能力，尤其是在開發中國家。面對如此高昂的成本，支付方和保險公司往往會設定嚴格的報銷標準和處方集限制。這限制了符合這些救命療法適用條件的患者群體，直接降低了關鍵國際市場的商業性銷售量，並阻礙了收入成長。

根據國際藥物經濟學與結果研究協會（ISPOR）2024年的數據，特定先進免疫療法的單療程費用已高達約31.8萬美元。如此高昂的價格給患者造成了沉重的經濟負擔（經濟毒性），也給國家醫療預算帶來了難以承受的壓力。因此，在對成本敏感的地區，市場難以實現廣泛滲透，因為這種經濟壓力迫使醫療政策制定者對治療進行發行或推遲高成本生物製藥的引入，從而有效地阻礙了該行業的潛在發展勢頭。

市場趨勢

隨著現有單株抗體專利的到期，市場正經歷著向癌症生物相似藥商業化的重大轉變。這一趨勢使醫療系統能夠採用成本效益更高的替代方案，這些方案既能保持臨床療效，又能緩解預算限制，從而擴大患者獲得必要生物療法的機會。製造商正積極拓展產品系列，以期在這個高銷售細分市場中佔據佔有率，挑戰原廠藥的主導地位。例如，山德士公司報告稱，截至2024年3月的會計年度，其生物製藥業務淨銷售額成長15%，達到22億美元，這主要得益於生物類似藥在全球範圍內的持續普及。

同時，製藥公司正優先開發皮下製劑，以取代傳統的靜脈輸注，用於已建立的癌症療法。這種改良策略旨在減輕輸液中心的後勤負擔，並透過顯著縮短給藥時間來提高患者的便利性。利用專有的酵素技術增強吸收，研發人員能夠透過快速注射而非長時間輸注的方式給藥高劑量生物製藥製劑。根據2024年9月的新聞稿（宣布基因泰克公司的TECENTRIQ Hybreza獲得FDA核准），這種新核准的皮下給藥方式將給藥時間縮短至約7分鐘，而標準靜脈注射通常需要30至60分鐘。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球癌症單株抗體市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 單株抗體類型（鼠源抗體、嵌合體抗體、人源化抗體）
  • 透過單株抗體療法（Bevacizumab（Avastin）、Rituximab（Rituxan）、曲妥珠單抗（Herceptin）、Cetuximab（愛必妥）、Panitumumab（Vectibix）等）
  • 依應用領域（乳癌、血癌、肝癌、腦瘤、結腸癌等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美癌症單株抗體市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章 歐洲癌症單株抗體市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區癌症單株抗體市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲癌症單株抗體市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美癌症單株抗體市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球癌症單株抗體市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Amgen Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Hoffmann-La Roche Ltd
• Genmab AS
• GlaxoSmithKline PLC
• Johnson & Johnson
• Novartis AG
• Merck & Co., Inc
• Spectrum Pharmaceuticals Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Cancer Monoclonal Antibodies Market is projected to expand from USD 99.66 Billion in 2025 to USD 244.95 Billion by 2031, reflecting a compound annual growth rate of 16.17%. These laboratory-engineered molecules function by binding to specific antigens on tumor cells, effectively flagging them for immune system elimination or inhibiting cell growth signals. The industry is primarily driven by the escalating global prevalence of malignancies, which necessitates the creation of targeted biologic therapies. Highlighting this urgent need, the American Cancer Society estimates that there will be 2,041,910 new cancer diagnoses in the United States alone in 2025. This increasing patient burden, combined with expedited regulatory pathways for immunotherapy agents, serves as a fundamental pillar supporting the sector's upward trajectory.

Despite these strong growth indicators, the market confronts significant obstacles due to the immense costs involved in the development and acquisition of these biologics. High production capital often results in elevated pricing structures, which limits accessibility in developing regions and places considerable strain on healthcare reimbursement systems. Consequently, strict pricing regulations and inadequate insurance coverage for premium immunotherapies persist as substantial barriers, potentially restricting the broader market penetration and commercial scalability of these advanced treatments.

Market Driver

A primary market driver is the rapid evolution of antibody engineering, specifically the transition from standard monoclonal antibodies to highly potent antibody-drug conjugates (ADCs) and bispecific constructs. These advanced modalities enable the precise delivery of cytotoxic payloads to tumor cells while minimizing systemic toxicity, effectively addressing past efficacy limitations and resistance issues. This technological progression is triggering major strategic consolidations as companies aim to acquire proprietary platforms to strengthen their portfolios. For instance, Johnson & Johnson announced in March 2024 that it had finalized an all-cash merger valued at approximately $2.0 billion with Ambrx to integrate a suite of next-generation ADCs targeting metastatic prostate cancer and other solid tumors, underscoring the industry's shift toward complex biologics with superior therapeutic profiles.

A second critical catalyst is the surging investment in oncology research and manufacturing infrastructure to support clinical pipelines and commercial supply chains. Pharmaceutical developers are dedicating substantial capital to establishing end-to-end production facilities to ensure the availability of these intricate drugs. A clear example of this is AstraZeneca's announcement in May 2024 regarding a capital expenditure of $1.5 billion to construct a greenfield manufacturing plant in Singapore dedicated to antibody-drug conjugates. This financial influx is heavily incentivized by the immense revenue potential of leading therapies; according to Merck & Co.'s February 2024 financial results, sales of their flagship antibody Keytruda grew by 19% to reach $25.0 billion, confirming the high return on investment available within this sector.

Market Challenge

The steep costs required to develop and acquire cancer monoclonal antibodies create a formidable barrier to the market's continued expansion. These biologic therapies involve complex manufacturing processes and rigorous clinical testing, resulting in high pricing structures that often exceed the financial capabilities of healthcare systems, particularly in developing nations. When payers and insurance providers face such elevated expenses, they frequently enforce strict reimbursement criteria or limit formulary inclusion. This restricts the patient population eligible for these life-saving treatments, directly reducing commercial volumes and hampering revenue growth in key international territories.

Data from the International Society for Pharmacoeconomics and Outcomes Research in 2024 indicates that the cost for a single course of certain advanced immunotherapy regimens has reached approximately $318,000. Such elevated price points generate severe financial toxicity for patients and impose unsustainable burdens on national health budgets. Consequently, the market struggles to achieve broad penetration in cost-sensitive regions, as this economic pressure compels healthcare decision-makers to ration care or delay the adoption of premium biologic agents, effectively stalling the industry's potential momentum.

Market Trends

The market is currently experiencing a significant shift toward the commercialization of oncology biosimilars as patents for legacy monoclonal antibodies begin to expire. This trend enables healthcare systems to adopt cost-effective alternatives that preserve clinical efficacy while mitigating budget constraints, thereby broadening patient access to essential biologic therapies. Manufacturers are aggressively expanding their portfolios to capture market share in this high-volume segment, challenging the dominance of originator drugs. For example, Sandoz reported in its March 2024 results that net sales for its biopharmaceuticals business grew by 15% to reach USD 2.2 billion, a performance largely driven by the continued global uptake of its biosimilar assets.

Simultaneously, pharmaceutical entities are prioritizing the development of subcutaneous formulations to replace traditional intravenous infusions for established cancer therapies. This reformulation strategy aims to alleviate the logistical burden on infusion centers and enhance patient convenience by drastically reducing the time required for treatment administration. By utilizing proprietary enzyme technologies to facilitate absorption, developers can deliver large-volume biologics via rapid injection rather than prolonged infusion. According to a September 2024 press release regarding the FDA approval of Genentech's Tecentriq Hybreza, this newly approved subcutaneous option reduces administration time to approximately seven minutes, compared to the 30 to 60 minutes typically required for standard intravenous delivery.

Key Market Players

• Amgen Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Hoffmann-La Roche Ltd
• Genmab AS
• GlaxoSmithKline PLC
• Johnson & Johnson
• Novartis AG
• Merck & Co., Inc
• Spectrum Pharmaceuticals Inc

Report Scope

In this report, the Global Cancer Monoclonal Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Monoclonal Antibodies Market, By Type of Monoclonal Antibody

• Murine Antibodies
• Chimeric Antibodies
• Humanized Antibodies

Cancer Monoclonal Antibodies Market, By Monoclonal Antibody Therapies

• Bevacizumab (Avastin)
• Rituximab (Rituxan)
• Trastuzumab (Herceptin)
• Cetuximab (Erbitux)
• Panitumumab (Vectibix)
• Other

Cancer Monoclonal Antibodies Market, By Application

• Breast Cancer
• Blood Cancer
• Liver Cancer
• Brain Cancer
• Colorectal Cancer
• Other

Cancer Monoclonal Antibodies Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Monoclonal Antibodies Market.

Available Customizations:

Global Cancer Monoclonal Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Monoclonal Antibodies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Monoclonal Antibody (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies)
  • 5.2.2. By Monoclonal Antibody Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other)
  • 5.2.3. By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cancer Monoclonal Antibodies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Monoclonal Antibody
  • 6.2.2. By Monoclonal Antibody Therapies
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cancer Monoclonal Antibodies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Monoclonal Antibody
      • 6.3.1.2.2. By Monoclonal Antibody Therapies
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Cancer Monoclonal Antibodies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Monoclonal Antibody
      • 6.3.2.2.2. By Monoclonal Antibody Therapies
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Cancer Monoclonal Antibodies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Monoclonal Antibody
      • 6.3.3.2.2. By Monoclonal Antibody Therapies
      • 6.3.3.2.3. By Application

7. Europe Cancer Monoclonal Antibodies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Monoclonal Antibody
  • 7.2.2. By Monoclonal Antibody Therapies
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cancer Monoclonal Antibodies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Monoclonal Antibody
      • 7.3.1.2.2. By Monoclonal Antibody Therapies
      • 7.3.1.2.3. By Application
  • 7.3.2. France Cancer Monoclonal Antibodies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Monoclonal Antibody
      • 7.3.2.2.2. By Monoclonal Antibody Therapies
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Cancer Monoclonal Antibodies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Monoclonal Antibody
      • 7.3.3.2.2. By Monoclonal Antibody Therapies
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Cancer Monoclonal Antibodies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Monoclonal Antibody
      • 7.3.4.2.2. By Monoclonal Antibody Therapies
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Cancer Monoclonal Antibodies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Monoclonal Antibody
      • 7.3.5.2.2. By Monoclonal Antibody Therapies
      • 7.3.5.2.3. By Application

8. Asia Pacific Cancer Monoclonal Antibodies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Monoclonal Antibody
  • 8.2.2. By Monoclonal Antibody Therapies
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cancer Monoclonal Antibodies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Monoclonal Antibody
      • 8.3.1.2.2. By Monoclonal Antibody Therapies
      • 8.3.1.2.3. By Application
  • 8.3.2. India Cancer Monoclonal Antibodies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Monoclonal Antibody
      • 8.3.2.2.2. By Monoclonal Antibody Therapies
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Cancer Monoclonal Antibodies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Monoclonal Antibody
      • 8.3.3.2.2. By Monoclonal Antibody Therapies
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Cancer Monoclonal Antibodies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Monoclonal Antibody
      • 8.3.4.2.2. By Monoclonal Antibody Therapies
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Cancer Monoclonal Antibodies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Monoclonal Antibody
      • 8.3.5.2.2. By Monoclonal Antibody Therapies
      • 8.3.5.2.3. By Application

9. Middle East & Africa Cancer Monoclonal Antibodies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Monoclonal Antibody
  • 9.2.2. By Monoclonal Antibody Therapies
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cancer Monoclonal Antibodies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Monoclonal Antibody
      • 9.3.1.2.2. By Monoclonal Antibody Therapies
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Cancer Monoclonal Antibodies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Monoclonal Antibody
      • 9.3.2.2.2. By Monoclonal Antibody Therapies
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Cancer Monoclonal Antibodies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Monoclonal Antibody
      • 9.3.3.2.2. By Monoclonal Antibody Therapies
      • 9.3.3.2.3. By Application

10. South America Cancer Monoclonal Antibodies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Monoclonal Antibody
  • 10.2.2. By Monoclonal Antibody Therapies
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cancer Monoclonal Antibodies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Monoclonal Antibody
      • 10.3.1.2.2. By Monoclonal Antibody Therapies
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Cancer Monoclonal Antibodies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Monoclonal Antibody
      • 10.3.2.2.2. By Monoclonal Antibody Therapies
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Cancer Monoclonal Antibodies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Monoclonal Antibody
      • 10.3.3.2.2. By Monoclonal Antibody Therapies
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cancer Monoclonal Antibodies Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Amgen Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bristol Myers Squibb Company
• 15.3. Eli Lilly and Company
• 15.4. Hoffmann-La Roche Ltd
• 15.5. Genmab AS
• 15.6. GlaxoSmithKline PLC
• 15.7. Johnson & Johnson
• 15.8. Novartis AG
• 15.9. Merck & Co., Inc
• 15.10. Spectrum Pharmaceuticals Inc

16. Strategic Recommendations

17. About Us & Disclaimer